Met Life Investment Management, LLC Altimmune, Inc. Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 44,534 shares of ALT stock, worth $185,706. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,534
Previous 46,870
4.98%
Holding current value
$185,706
Previous $181,000
7.73%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALT
# of Institutions
195Shares Held
40.1MCall Options Held
3.82MPut Options Held
2.8M-
Vanguard Group Inc Valley Forge, PA6.37MShares$26.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.32MShares$22.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.6MShares$15 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.13MShares$8.89 Million0.37% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$8.41 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $204M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...